Sorrento Therapeutics, Scintilla give operating results for March

By Sarah Lizee

Olympia, Wash., May 19 – Sorrento Therapeutics, Inc. reported a $72.1 million net loss for March on $40,053 of gross income/sales, according to its monthly operating report filed Wednesday with the U.S. Bankruptcy Court for the Southern District of Texas.

Sorrento’s cash balance at the end of March was $20.4 million.

The Scintilla Pharmaceuticals, Inc. debtor reported zero profit and zero gross income/sales for March and a cash balance of $60,000 at the end of the month.

The biopharmaceutical company is based in San Diego. The company filed bankruptcy on Feb. 13 under Chapter 11 case number 23-90085.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.